儿科疫苗市场、机会、成长动力、产业趋势分析与预测，2024-2032

在合作伙伴关係和投资不断增加的推动下，儿科疫苗市场规模预计 2024 年至 2032 年间复合年增长率将达到 8.9%。

最近，各组织正合作加强研发活动，为儿童生产更有效、更容易取得的疫苗。这些投资为新疫苗配方和技术铺平了道路，增强了对一系列疾病的保护。这种对投资和合作的坚定承诺确保疫苗与健康挑战同步发展，最终促进全球儿童获得更好的健康结果。例如，2023 年 9 月，葛兰素史克 (GSK) 与救助儿童会 (Save the Children) 的合作关係又延长了五年。葛兰素史克 (GSK) 正在拨款 1500 万英镑来提高疫苗接种率，特别关注埃塞俄比亚和尼日利亚的「零剂量」儿童。

儿科疫苗产业根据类型、技术、适应症、最终用途和地区进行细分。

由于人们越来越倾向于针对单一病原体或其特定菌株，因此单价疫苗类型细分市场的市场份额预计到 2032 年将大幅增长。单价疫苗透过集中针对单一病毒或细菌来针对儿科族群中的疾病。这些疫苗正在接受严格的临床试验，以增强其功效和安全性。因此，不断取得的进步正在对单价疫苗进行微调，使其不仅更有效，而且更容易管理，从而增强儿科护理中的疾病预防。

就最终用途而言，由于越来越重视儿童及时有效的免疫接种，私部门的儿科疫苗市场价值预计将在 2024 年至 2032 年期间产生可观的收入。医疗机构正在加强疫苗接种服务，以确保年轻患者获得彻底的免疫接种。私人诊所正在实现产品多元化，提供广泛的儿科疫苗，以满足各种健康需求和预防疾病。此外，疫苗技术和给药方法的创新正在提高私人诊所中儿科疫苗的有效性和便利性。

在全球健康倡议的带动下，到 2032 年，欧洲儿科疫苗产业规模可能会显着成长。一些国家正在联手实施旨在透过全面的疫苗接种策略来促进儿童健康的计画。随着全球卫生组织加强扩大疫苗覆盖率，欧洲医疗保健提供者正在透过加强其私人疫苗接种服务来应对。这项持续的合作旨在提高整个欧洲儿童的疫苗接种率并改善健康。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 儿童慢性病和传染病的发生率上升
    • 出生率增加
    • 疫苗开发的研究和开发活动不断增加
    • 政府措施和资金不断增加
  • 产业陷阱与挑战
    • 已开发国家疫苗审批监管严格
• 成长潜力分析
• 监管环境
• 管道分析
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

• 主要趋势
• 单价疫苗
• 多价疫苗

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

• 主要趋势
• 减毒活疫苗
• 灭活疫苗
• 类毒素疫苗
• 结合疫苗
• 其他技术

第 7 章：市场估计与预测：按指标划分，2021 - 2032 年

• 主要趋势
• 流感
• 人类乳突病毒
• 麻疹、腮腺炎和德国麻疹
• 小儿麻痹
• 肺炎球菌疾病
• 白喉、百日咳和破伤风
• 其他适应症

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 民众
• 私人的

第 9 章：市场估计与预测：按地区，2021 - 2032

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋
  • 中东和非洲其他地区

第 10 章：公司简介

• Astellas Pharma, Inc.
• AstraZeneca Plc
• CSL Limited
• Daiichi Sankyo Company Limited
• Emergent BioSolutions, Inc,
• GlaxoSmithKline Plc
• Grifol SA
• Meissa Vaccines, Inc.
• Merck and Co. Inc.
• Panacea Biotec
• Pfizer, Inc.
• Sanofi SA
• Serum Institute of India
• Takeda Pharmaceutical Industries Limited

Pediatric Vaccines Market size is expected to record an 8.9% CAGR between 2024 and 2032, driven by increasing partnerships and investments.

Of late, organizations are collaborating to bolster R and D activities to produce more effective and accessible vaccines for children. These investments are paving the way for new vaccine formulations and technologies, enhancing protection against a range of diseases. This steadfast commitment to investment and collaboration ensures that vaccines evolve in tandem with health challenges for ultimately promoting better health outcomes for children globally. For example, in September 2023, GSK and Save the Children extended their partnership for another five years. GSK is channeling £15 million to elevate vaccination rates, with a particular focus on 'zero dose' children in Ethiopia and Nigeria.

The pediatric vaccines industry is segmented based on type, technology, indication, end-use, and region.

The market share from the monovalent vaccines type segment is expected to witness substantial growth through 2032, due to the rising preference for targeting individual pathogens or their specific strains. Monovalent vaccines focus on diseases within pediatric populations by concentrating on a singular virus or bacterium. These vaccines are undergoing stringent clinical trials to bolster their efficacy and safety. As a result, ongoing advancements are fine-tuning monovalent vaccines, making them not only more effective but also easier to administer, thereby amplifying disease prevention in pediatric care.

In terms of end-use, the pediatric vaccines market value from the private segment is slated to generate notable revenue during 2024-2032 driven by the growing emphasis on timely and effective immunizations for children. Healthcare facilities are ramping up their vaccination services to ensure thorough immunization for their young patients. Private clinics are diversifying their offerings, providing a broad spectrum of pediatric vaccines to meet various health needs and prevent diseases. Furthermore, innovations in vaccine technology and delivery methods are boosting the effectiveness and ease of pediatric vaccines in private practices.

Europe pediatric vaccines industry size is likely to record a significant growth rate through 2032 led by global health initiatives. Several countries are joining forces on programs aimed at bolstering child health through comprehensive vaccination strategies. With global health organizations intensifying their efforts to amplify vaccine coverage, European healthcare providers are responding by enhancing their private vaccination services. This ongoing collaboration is set to elevate vaccination rates and improve health outcomes for children throughout Europe.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of chronic and infectious disease in children
    • 3.2.1.2 Increasing birth rate
    • 3.2.1.3 Growing research and development activities for vaccine development
    • 3.2.1.4 Rising government initiatives and funding
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulations for the approval of vaccines in developed nations
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Monovalent vaccines
• 5.3 Multivalent vaccines

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Live attenuated vaccines
• 6.3 Inactivated vaccines
• 6.4 Toxoid vaccines
• 6.5 Conjugate vaccines
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Influenza
• 7.3 Human papilloma virus
• 7.4 Measles, mumps, and rubella
• 7.5 Polio
• 7.6 Pneumococcal disease
• 7.7 Diphtheria, pertussis, and tetanus
• 7.8 Other indications

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Public
• 8.3 Private

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 Astellas Pharma, Inc.
• 10.2 AstraZeneca Plc
• 10.3 CSL Limited
• 10.4 Daiichi Sankyo Company Limited
• 10.5 Emergent BioSolutions, Inc,
• 10.6 GlaxoSmithKline Plc
• 10.7 Grifol SA
• 10.8 Meissa Vaccines, Inc.
• 10.9 Merck and Co. Inc.
• 10.10 Panacea Biotec
• 10.11 Pfizer, Inc.
• 10.12 Sanofi SA
• 10.13 Serum Institute of India
• 10.14 Takeda Pharmaceutical Industries Limited